

Zu-Yau Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6458090/publications.pdf>

Version: 2024-02-01

130
papers

2,393
citations

236833

25
h-index

265120

42
g-index

132
all docs

132
docs citations

132
times ranked

2734
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. <i>Cancer</i> , 1992, 69, 2052-2054.	2.0	116
2	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	1.8	110
3	Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 461-469.	0.8	100
4	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. <i>Journal of Medical Virology</i> , 2001, 65, 58-65.	2.5	97
5	Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. <i>Medicine (United States)</i> , 2015, 94, e690.	0.4	94
6	Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 525-529.	2.5	83
7	Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. <i>Liver</i> , 1994, 14, 98-102.	0.1	80
8	Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 454-458.	2.5	71
9	Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. <i>Life Sciences</i> , 2013, 93, 323-328.	2.0	61
10	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	1.8	60
11	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1754-1762.	1.4	59
12	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 636-640.	1.4	56
13	Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 68-73.	0.8	54
14	Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. <i>Oncotarget</i> , 2015, 6, 23987-24001.	0.8	51
15	Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2933-2939.	1.8	46
16	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	1.9	44
17	Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: A case-control study. <i>International Journal of Cancer</i> , 1994, 56, 619-621.	2.3	40
18	The role of hepatitis C virus in chronic hepatitis B virus infection. <i>Gastroenterologia Japonica</i> , 1993, 28, 23-27.	0.4	33

#	ARTICLE	IF	CITATIONS
19	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 1690-1697.	3.2	32
20	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	4.5	32
21	Serial serum VEGF, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 314-322.	0.8	30
22	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, 512-518.	1.8	30
23	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. <i>EBioMedicine</i> , 2017, 15, 81-89.	2.7	30
24	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- α plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 1015-1020.	0.6	29
25	Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 312-318.	0.8	28
26	Incidence and clinical significance of spontaneous intrahepatic portosystemic venous shunts detected by sonography in adults without potential cause. <i>Journal of Clinical Ultrasound</i> , 2006, 34, 22-26.	0.4	25
27	The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 567-571.	0.8	25
28	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	1.9	23
29	Circulating immune complexes in chronic hepatitis C. <i>Journal of Medical Virology</i> , 1995, 46, 12-17.	2.5	22
30	Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 417-421.	1.4	22
31	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 362-366.	0.8	22
32	Pharmacologic concentrations of melatonin have diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 659-662.	2.5	21
33	Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 348-351.	2.5	20
34	Cure or curd: Modification of lipid profiles and cardiovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 920-928.	0.8	20
35	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017, 12, e0178883.	1.1	18
36	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. <i>BMJ Open</i> , 2019, 9, e026703.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. <i>Liver International</i> , 2021, 41, 956-968.	1.9	17
38	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
39	Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors. <i>Liver</i> , 1997, 17, 24-29.	0.1	16
40	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014, 105, 135-142.	1.9	16
41	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. <i>PLoS ONE</i> , 2015, 10, e0139796.	1.1	16
42	25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. <i>Hepatology Research</i> , 2017, 47, 1383-1389.	1.8	16
43	Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0122259.	1.1	16
44	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 518-526.	0.8	15
45	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. <i>PLoS ONE</i> , 2019, 14, e0220663.	1.1	15
46	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1224-1233.	1.9	15
47	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1768-1774.	1.4	14
48	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. <i>Hepatology International</i> , 2018, 12, 544-551.	1.9	14
49	Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. <i>Oncogene</i> , 2022, 41, 3011-3023.	2.6	14
50	Association of hyperuricemia with disease severity in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018, 13, e0207043.	1.1	13
51	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	1.1	13
52	Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 229-234.	0.8	12
53	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 99-104.	0.6	12
54	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017, 8, 43925-43933.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Antibodies to hepatitis E virus among chinese patients with acute hepatitis in Taiwan. <i>Journal of Medical Virology</i> , 1994, 43, 341-344.	2.5	11
56	Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 554-559.	0.8	11
57	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 77-82.	0.8	11
58	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 44-49.	0.8	11
59	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	1.6	11
60	Clinical application of serum C-reactive protein measurement in the detection of bacterial infection in patients with liver cirrhosis. <i>Kaohsiung Journal of Medical Sciences</i> , 2002, 18, 121-6.	0.8	11
61	Safety of fine-needle aspiration in patients with small hepatocellular carcinoma. <i>Hepatology Research</i> , 2005, 31, 31-35.	1.8	10
62	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. <i>Oncotarget</i> , 2018, 9, 21313-21321.	0.8	10
63	Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 249-255.	1.4	10
64	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021, 11, e042861.	0.8	10
65	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	1.4	10
66	Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 398-405.	1.4	9
67	Relapsed Acute Pancreatitis as the Initial Presentation of Pancreatic Cancer in a Young Man: A Case Report. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 448-455.	0.8	9
68	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015, 5, 11901.	1.6	9
69	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein expression predicts disease severity in chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 394-399.	0.8	9
70	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4945.	1.8	9
71	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	4.5	9
72	Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 201.	0.8	8

#	ARTICLE	IF	CITATIONS
73	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 624-632.	0.8	8
74	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066.	0.4	8
75	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
76	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 145-153.	0.8	8
77	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	0.8	8
78	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 616-623.	0.8	8
79	High therapeutic concentration of prazosin up-regulates angiogenic IL6 and CCL2 genes in hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 583-586.	2.5	7
80	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	1.6	7
81	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 473-481.	1.4	7
82	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016, 7, 61325-61335.	0.8	7
83	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	1.3	7
84	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 14-23.	0.8	6
85	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1108-1114.	1.4	6
86	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. <i>Scientific Reports</i> , 2018, 8, 15821.	1.6	6
87	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 151-156.	1.4	6
88	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	0.6	6
89	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. <i>PLoS ONE</i> , 2021, 16, e0254028.	1.1	6
90	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. <i>Oncotarget</i> , 2017, 8, 32618-32625.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
92	Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2017, 86, 27-31.	2.5	5
93	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0184878.	1.1	5
94	Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. <i>Scientific Reports</i> , 2018, 8, 15058.	1.6	5
95	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 277-281.	0.6	5
96	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5
97	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	1.0	5
98	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018, 9, 12240-12249.	0.8	5
99	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	1.1	5
100	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2022, 16, 59-67.	1.9	5
101	Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 431-436.	0.8	4
102	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. <i>Hepatology International</i> , 2012, 6, 613-619.	1.9	4
103	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. <i>Hepatology International</i> , 2013, 7, 162-170.	1.9	4
104	Clinical utility of a simple primary culture method in hepatocellular carcinoma patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 352-357.	1.4	4
105	Disease severity and erythropoiesis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 864-869.	1.4	4
106	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa272.	0.4	4
107	Acute Pancreatitis Complicated with Transient Portal Venous Thrombosis in One Patient with Hepatocellular Carcinoma and Cirrhosis. <i>Kaohsiung Journal of Medical Sciences</i> , 2007, 23, 254-258.	0.8	3
108	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 271-277.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Independent and additive interaction between polymorphisms of <i>tumor necrosis factor Î±</i> 308 and <i>lymphotoxin Î±</i> +252 on risk of hepatocellular carcinoma related to hepatitis B. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 453-457.	0.8	3
110	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 54-62.	0.8	3
111	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 460-466.	0.8	3
112	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype 2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	0.8	3
113	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. <i>Biomedicines</i> , 2021, 9, 1446.	1.4	3
114	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. <i>Cancers</i> , 2022, 14, 2023.	1.7	3
115	Influence of silibinin on differential expressions of total cytokine genes in human hepatocellular carcinoma cell lines. <i>Biomedicine and Preventive Nutrition</i> , 2011, 1, 91-94.	0.9	2
116	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013, 7, 180-187.	1.9	2
117	Variable uptake feature of focal nodular hyperplasia in Tc-99m phytate hepatic scintigraphy/single-photon emission computed tomography: A parametric analysis. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 621-625.	0.8	2
118	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 559-566.	0.8	2
119	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 284-289.	0.8	2
120	Interactive effects between <i>Lymphotoxin Î±</i> +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 334-338.	0.8	2
121	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	0.8	2
122	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	1.4	2
123	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
124	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
125	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	2
126	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. , 2001, 65, 58.		1

#	ARTICLE	IF	CITATIONS
127	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high <i>NANOG</i> expression. Kaohsiung Journal of Medical Sciences, 2022, 38, 157-164.	0.8	1
128	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	1.7	0
129	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. American Journal of Medicine, 2019, 132, e41-e42.	0.6	0
130	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3239-3246.	1.4	0